α-Santalol/Sandalwood oil / Casp8 Cancer Research Results

SAO, α-Santalol/Sandalwood oil: Click to Expand ⟱
Features:

α-Santalol / Sandalwood oil — α-Santalol is a lipophilic sesquiterpene alcohol and major bioactive constituent of East Indian sandalwood oil from Santalum album. It is best classified as a natural-product small molecule / essential-oil sesquiterpenoid, with sandalwood oil functioning as a botanical mixture source rather than a single-compound drug. Standard abbreviations include α-SAN, alpha-santalol, and SAO or EISO for sandalwood album / East Indian sandalwood oil. The oncology evidence is primarily preclinical, strongest for skin, prostate, breast, and oral cancer models, with no established oncology indication.

Primary mechanisms (ranked):

  1. Induction of intrinsic and extrinsic apoptosis through caspase activation, PARP cleavage, mitochondrial involvement, and increased apoptotic signaling.
  2. Cell-cycle blockade, especially G2/M arrest, with reported tubulin interaction and mitotic disruption in oral cancer models.
  3. Suppression of AKT–survivin / IAP survival signaling, including reduced p-AKT, survivin, XIAP, PCNA, cyclin D, and CDC2 in prostate cancer models.
  4. Anti-migration and anti-invasive signaling through Wnt/β-catenin inhibition in breast cancer models.
  5. Anti-angiogenic signaling through VEGFR2–AKT/mTOR/p70S6K pathway suppression in prostate tumor models.
  6. Autophagy modulation, including AKT–mTOR-linked autophagy in prostate cancer and autophagy/cell death effects for whole sandalwood oil in proliferating keratinocytes.
  7. Skin chemopreventive modulation of UVB/chemical carcinogenesis pathways, including p53/caspase-associated apoptosis and inflammatory stress-response modulation.

Bioavailability / PK relevance: α-Santalol is a small, highly lipophilic sesquiterpene alcohol, so topical and transdermal exposure is plausible, but formal human systemic PK data are limited. Oral/transdermal use should be treated as formulation- and dose-dependent, and essential-oil exposure is not equivalent to purified α-santalol exposure.

In-vitro vs systemic exposure relevance: Most anticancer cell-culture studies use micromolar α-santalol concentrations, commonly around 20–75 μM depending on model and endpoint. These levels should be considered potentially above reliably documented human systemic exposure from sandalwood oil use, so in-vitro anticancer potency should not be interpreted as clinically achievable without dedicated PK/formulation data.

Clinical evidence status: Preclinical for cancer prevention/therapy. Small human and dermatology-oriented evidence exists for sandalwood album oil in non-oncology skin conditions, and one clinical-trial context appears related to oral mucositis/supportive care rather than anticancer efficacy. No approved oncology indication and no high-quality human RCT evidence for cancer treatment were identified.

α-Santalol and Sandalwood Oil Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Caspase apoptosis ↑ caspase-3, ↑ caspase-8, ↑ caspase-9, ↑ PARP cleavage, ↓ viability ↔ to modest toxicity at comparable experimental windows (model-dependent) R/G Pro-apoptotic anticancer effect Core mechanism across prostate, breast, and skin cancer models; includes intrinsic and extrinsic apoptotic signaling.
2 Mitochondria / MPTP ↑ mitochondrial apoptotic signaling, ↓ mitochondrial membrane integrity (model-dependent) ↔ uncertain R/G Amplifies apoptosis Mitochondrial involvement is supported mainly through caspase-9 and apoptotic readouts; direct MPTP evidence is not as strong as apoptosis evidence.
3 Cell cycle and tubulin ↑ G2/M arrest, ↓ tubulin polymerization, ↑ mitotic arrest ↔ uncertain G Anti-proliferative cytostasis and cytotoxicity Strong mechanistic relevance for oral cancer and skin/breast cancer models; tubulin interaction supports antimitotic classification.
4 AKT / survivin / IAP ↓ p-AKT, ↓ survivin, ↓ XIAP, ↓ PCNA, ↓ cyclin D, ↓ CDC2 ↔ uncertain G Reduces survival signaling and proliferation Important prostate-cancer axis; PI3K/AKT inhibition can enhance α-santalol-induced apoptosis.
5 Wnt / β-catenin migration ↓ β-catenin-linked migration and motility ↔ uncertain G Anti-migration effect Best supported in cultured breast cancer cells; therapeutic relevance remains preclinical.
6 VEGFR2 angiogenesis ↓ VEGFR2 signaling, ↓ AKT/mTOR/p70S6K, ↓ tumor angiogenesis ↔ uncertain G Anti-angiogenic effect Relevant to prostate tumor xenograft-type evidence; not yet clinically validated.
7 Autophagy / AKT-mTOR ↑ autophagy (context-dependent), ↓ AKT-mTOR signaling ↑ autophagy/cell death in proliferating keratinocytes with whole oil (context-dependent) G Context-dependent stress adaptation or cell death Autophagy may be protective in some prostate cancer contexts; combination strategies would need caution.
8 ROS / oxidative stress ↔ limited direct cancer-specific evidence for α-santalol as a primary ROS driver ↔ antioxidant effects reported in non-cancer models R/G Secondary or context-dependent redox modulation ROS is not a core anticancer mechanism unless a specific model/source directly shows ROS-dependent killing.
9 NRF2 ↔ insufficient direct α-santalol cancer evidence ↔ uncertain G Not a primary assigned mechanism
10 Glycolysis / HIF-1α ↔ insufficient direct evidence ↔ insufficient direct evidence G No clear primary modulation
11 Radiosensitization or chemosensitization ↔ limited direct evidence; possible apoptosis-combination rationale only ↔ uncertain G Unproven adjunct effect
12 Clinical Translation Constraint In-vitro potency may require exposure above documented human systemic levels Topical irritation or sensitization possible; systemic safety data limited G Limits clinical interpretation Major constraints are formulation, bioavailability, mixture variability, topical safety, and lack of oncology trials.

P: 0–30 min R: 30 min–3 hr G: >3 hr



Casp8, CASP8, caspase 8, apoptosis-related cysteine peptidase: Click to Expand ⟱
Source: CGL-Driver Genes
Type: TSG
Caspase-8 is a unique member of caspases with a dual role in cell death and survival. Caspase-8 expression is often lost in some tumors, but increased in others, indicating a potential pro-survival function in cancer.
Caspase-8 (Casp8) acts as an initiator in cell apoptosis signaling. However, the role of Casp8 in tuning the tumor immune microenvironment remains controversial due to the complicated crosstalk between immune-tolerogenic apoptotic cell death and immunogenic cell death cascades.


Scientific Papers found: Click to Expand⟱
6442- SAO,    Medicinal properties of alpha-santalol, a naturally occurring constituent of sandalwood oil: review
- Review, RCC, NA
AntiTum↑, Apoptosis↑, TumCCA↑, *Inflam↓, selectivity↑, tumCV↓, Casp8↓, Casp9↓, Casp6↓, Casp3↓, cl‑PARP↑, angioG↓, VEGFR2↓, Akt↑, mTOR↓, TumCG↓, *GSTs↑, *antiOx↑, *ROS↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death

Akt↑, 1,   Apoptosis↑, 1,   Casp3↓, 1,   Casp6↓, 1,   Casp8↓, 1,   Casp9↓, 1,  

Transcription & Epigenetics

tumCV↓, 1,  

DNA Damage & Repair

cl‑PARP↑, 1,  

Cell Cycle & Senescence

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State

mTOR↓, 1,   TumCG↓, 1,  

Angiogenesis & Vasculature

angioG↓, 1,   VEGFR2↓, 1,  

Drug Metabolism & Resistance

selectivity↑, 1,  

Functional Outcomes

AntiTum↑, 1,  
Total Targets: 15

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 1,   GSTs↑, 1,   ROS↓, 1,  

Immune & Inflammatory Signaling

Inflam↓, 1,  
Total Targets: 4

Scientific Paper Hit Count for: Casp8, CASP8, caspase 8, apoptosis-related cysteine peptidase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:407  Target#:44  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page